Saccharomyces

Saccharomyces in stool often reflects yeast from food or supplements. S. cerevisiae is used to make bread and beer; S. boulardii is a probiotic variety of that species. This DNA-based stool result covers the Saccharomyces group; it doesn't identify a particular probiotic strain or show whether the detected yeast is alive.

Its clinical use remains exploratory. Human studies have linked stool fungal patterns to inflammatory bowel disease, C. difficile infection, diabetes, and colorectal cancer. Those associations haven't established a healthy target or shown that using this result to guide treatment improves health.

Why It Appears in Stool

Saccharomyces yeasts are single-celled fungi found in food, drinks, and supplements. They are among the fungi commonly detected in human stool. A study of 923 adults in Poland found Saccharomyces to be the most prevalent fungal genus among samples containing detectable fungi.

Small controlled-diet studies support food as an important source, and probiotic studies show that live yeast can survive passage through the digestive tract. Detection during that passage doesn't establish lasting residence in the gut. A stool sample also represents material leaving the intestine, so it cannot show whether yeast is attached to or invading the intestinal lining.

Ulcerative Colitis

Ulcerative colitis causes inflammation and sores in the colon's lining. In a study with stool fungal data from 82 people, the colonoscopy comparison involved 43 participants. Saccharomyces and Candida were more abundant in those with active inflammation than in those in remission, after accounting for age, sex, and use of medicines that target specific immune processes.

That finding runs against much of the earlier research. Several other studies have reported less S. cerevisiae in inflammatory bowel disease, including ulcerative colitis, often alongside more Candida. So the direction of the link between this yeast and colitis activity isn't settled.

A pediatric study found more stool Saccharomyces in children with both ulcerative colitis and primary sclerosing cholangitis. The latter condition scars the bile ducts. A separate adult study found less S. cerevisiae in people with that bile-duct disease. The adult finding concerned one species within the group reported here. Differences in age, disease, diet, and analysis make these studies difficult to compare.

These studies compared groups of people. They haven't shown that a rise in your stool Saccharomyces predicts a flare or adds useful information to established inflammation monitoring.

Crohn's Disease

Crohn's disease can cause inflammation anywhere in the digestive tract. A systematic review of 27 case-control studies found inconsistent fungal findings across inflammatory bowel disease. In Crohn's disease, increases in Candida or Malassezia were often accompanied by lower Saccharomyces.

A separate analysis of stool sequencing data found different directions of association for S. cerevisiae across countries. The apparent increases in the US and Spanish Crohn's groups weren't statistically reliable, and the species-level findings did not survive adjustment for the many comparisons being made. They shouldn't be treated as a reproducible disease signature.

Diet is one possible contributor to these differences, alongside medication, geography, disease features, and measurement methods. The studies don't establish which factor explains the disagreements, or whether changing this yeast would improve Crohn's disease.

C. difficile Infection and Relapse

C. difficile is a bacterium that can cause diarrhea and colon inflammation, often during or after antibiotic use. Studies of affected people have found changes in their stool fungal communities, but no Saccharomyces pattern is established for diagnosing infection or predicting recurrence in an individual.

In a small study of fecal microbiota transplantation for recurrent infection, successful treatment was associated with a greater relative abundance of Saccharomyces and Aspergillus afterward. Candida dominated in people whose treatment failed. This was an association with a treatment outcome; it didn't show that increasing Saccharomyces caused recovery.

Another study combined several stool fungal measurements with blood immune markers to distinguish infection from symptom-free carriage. Its best-performing combination did not include Saccharomyces. That experimental model cannot be used as evidence that this single stool result detects C. difficile.

Type 2 Diabetes

An analysis of 10,695 Chinese adults found a positive association between stool Saccharomyces and existing type 2 diabetes. People above the study median for both yeast abundance and a conventional diabetes risk score had about four times the odds of diabetes compared with those below both medians. Among people with a lower conventional risk score, higher yeast abundance was associated with about 30% higher odds.

That result isn't the consensus. Other, smaller studies have mostly reported the opposite direction, with less stool Saccharomyces in people with diabetes, so even the direction of this link is unresolved.

The larger comparison combines yeast abundance with established risk factors, including age, body size, and blood pressure. It isn't the effect of the yeast alone. These results concern the odds of already having diabetes and don't establish that a stool result predicts your future risk or that lowering the yeast prevents diabetes.

Colorectal Cancer

A stool-sequencing study found less S. cerevisiae in people with colorectal cancer than in controls. That finding concerns one species within this broader yeast group. The research hasn't established stool Saccharomyces as a cancer screening test, and a high or low result cannot rule cancer in or out.

When Results Can Be Misleading

• Food and supplements: recent yeast-containing foods or yeast probiotics can change the result without showing that your gut health has improved or worsened.
• Diarrhea: a study using stool cultures found lower S. boulardii concentrations during diarrhea. That finding doesn't provide a correction factor for this DNA-based result.
• Live versus dead yeast: DNA can remain detectable when yeast is no longer alive. Detection alone doesn't establish growth, infection, or probiotic activity.
• Genus versus strain: this result combines related yeasts. It cannot separate a probiotic strain from food-associated Saccharomyces.
• Relative versus absolute abundance: many research studies report the share of fungal DNA belonging to a group. That share can change when other fungi change, even if the amount of Saccharomyces stays the same.
• Collection and analysis: storage, DNA extraction, the sequences examined, and contamination can affect detection. Very small signals need particular caution, and results from different methods aren't interchangeable.

What Changes Over Time Mean

Repeated results may document changes in what is detected in your stool. A higher or lower number has no established meaning as improvement or deterioration, even when compared with your own earlier result. Studies haven't validated serial Saccharomyces testing to guide probiotic dosing, monitor bowel disease, or prevent future illness.